Serina Therapeutics, Inc. financial data

Symbol
SER on NYSE
Location
601 Genome Way, Suite 2001, Huntsville, AL
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 11, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 114 % +34.1%
Debt-to-equity -415 % -554%
Return On Equity 498 % +1861%
Return On Assets -169 % -157%
Operating Margin -17.1K % -7239%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 10.3M shares +15.4%
Common Stock, Shares, Outstanding 10.1M shares +15.4%
Entity Public Float 38.4M USD +105%
Common Stock, Value, Issued 1K USD 0%
Weighted Average Number of Shares Outstanding, Basic 10M shares +17.5%
Weighted Average Number of Shares Outstanding, Diluted 10M shares -1.51%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 130K USD -95.9%
Cost of Revenue 40K USD +208%
Research and Development Expense 10.9M USD +159%
General and Administrative Expense 11.5M USD +81%
Operating Income (Loss) -22.3M USD -201%
Nonoperating Income (Expense) 9.63M USD +2475%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -12.6M USD -79.7%
Earnings Per Share, Basic 2 USD/shares -208%
Earnings Per Share, Diluted 2 USD/shares -229%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 6.04M USD -0.38%
Accounts Receivable, after Allowance for Credit Loss, Current 65K USD +983%
Other Assets, Current 177K USD +8750%
Assets, Current 7.99M USD -10.4%
Property, Plant and Equipment, Net 588K USD +8.89%
Operating Lease, Right-of-Use Asset 362K USD -35.6%
Intangible Assets, Net (Excluding Goodwill) 509K USD -20.5%
Assets 8.94M USD -16.5%
Accounts Payable, Current 1.71M USD +41.8%
Accrued Liabilities, Current 1.31M USD +309%
Liabilities, Current 3.56M USD -71.8%
Operating Lease, Liability, Noncurrent 185K USD -48.9%
Liabilities 7.3M USD -73.1%
Retained Earnings (Accumulated Deficit) -55.6M USD -29.3%
Stockholders' Equity Attributable to Parent 1.8M USD
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 1.65M USD
Liabilities and Equity 8.94M USD -16.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.32M USD -174%
Net Cash Provided by (Used in) Financing Activities 4.92M USD +80.2%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 40M shares 0%
Common Stock, Shares, Issued 10.1M shares +15.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 595K USD -47.7%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1K USD -92.9%
Deferred Tax Assets, Valuation Allowance 35.4M USD +176%
Deferred Tax Assets, Gross 35.7M USD +175%
Operating Lease, Liability 362K USD -35.6%
Depreciation 0 USD
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid 391K USD -36.5%
Property, Plant and Equipment, Gross 1.22M USD +25.1%
Operating Lease, Liability, Current 177K USD -11.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 117K USD -26.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 159K USD -26.7%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 29K USD -46.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 10K USD -91.5%
Deferred Tax Assets, Operating Loss Carryforwards 22.5M USD +121%
Preferred Stock, Shares Issued 965K shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 816K USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 10K USD
Operating Lease, Payments 56K USD +1.82%
Additional Paid in Capital 52.4M USD +97%
Preferred Stock, Shares Outstanding 965K shares
Amortization of Intangible Assets 101K USD -22.9%
Deferred Tax Assets, Net of Valuation Allowance 226K USD +61.4%
Share-based Payment Arrangement, Expense 3.93M USD +668%
Interest Expense 4.91M USD +72.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%